Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 654

1.

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.

Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV; GAL-INT-6 Study Group..

Clin Ther. 2003 Jun;25(6):1765-82. Erratum in: Clin Ther. 2003 Aug;25(8):2336.

PMID:
12860497
2.
3.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
4.
5.

A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.

Suh GH, Yeon Jung H, Uk Lee C, Hoon Oh B, Nam Bae J, Jung HY, Ju YS, Kil Yeon B, Park J, Hong I, Choi S, Ho Lee J; Korean Galantamine Study Group..

Clin Ther. 2004 Oct;26(10):1608-18.

PMID:
15598477
6.

Galantamine treatment of vascular dementia: a randomized trial.

Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C; GAL-INT-26 Study Group..

Neurology. 2007 Jul 31;69(5):448-58.

PMID:
17664404
7.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
8.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
9.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
10.

Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.

Bullock R, Erkinjuntti T, Lilienfeld S; GAL-INT-6 Study Group..

Dement Geriatr Cogn Disord. 2004;17(1-2):29-34. Epub 2003 Oct 13.

PMID:
14560062
11.

Long-term outcomes of galantamine treatment in patients with Alzheimer disease.

Lyketsos CG, Reichman WE, Kershaw P, Zhu Y.

Am J Geriatr Psychiatry. 2004 Sep-Oct;12(5):473-82.

PMID:
15353385
13.
14.

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.

Chu LW, Yik PY, Mok W, Chung CP.

Int J Clin Pract. 2007 Mar;61(3):403-10.

PMID:
17313606
15.

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D.

J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95.

16.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
17.

Effects of galantamine in patients with mild Alzheimer's disease.

Orgogozo JM, Small GW, Hammond G, Van Baelen B, Schwalen S.

Curr Med Res Opin. 2004 Nov;20(11):1815-20.

PMID:
15537482
18.

Galantamine for vascular cognitive impairment.

Craig D, Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004746. Review. Update in: Cochrane Database Syst Rev. 2013;4:CD004746.

PMID:
16437493
19.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
20.

Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.

Rockwood K, Dai D, Mitnitski A.

Int J Geriatr Psychiatry. 2008 Feb;23(2):207-14.

PMID:
17621382

Supplemental Content

Support Center